Cell & Gene
Across the Cell & Gene Technologies (CGT), Personalized Medicine and Bioscience businesses, we continue to grow in response to market demand, while developing new and differentiated tools and technologies for emerging modalities. The CGT business grew significantly over the course of 2020, by advancing the commercialization of multiple programs while initiating several new Investigational New Drugs (INDs) and continuing to industrialize operations. Double-digit growth rates have been maintained in both Viral Vector and Cell Therapy across development services and cGMP supply.
We continue to focus on vein-to-vein networks, by establishing a network of collaborations (with partners including Be The Match Biotherapies, Vinetti and Cryoport). These collaborations will enable us to link apheresis with cold chain and tracking across the CGT supply chain. We have also formed internal collaborations to incorporate our MODA-ES® electronic batch system to create a full chain of custody through the patient value chain.
Our proprietary Cocoon® Platform, which automates the production of autologous cell therapies was used for the first time to treat a patient with CAR-T therapy. This has resulted in extensive interest from other renowned cancer treatment centers and universities, which are also interested in developing patient-specific therapies.
Market demand for Bioscience products was temporarily impacted by the COVID-19 pandemic during Q2, as many academic and research centers were closed. However, demand bounced back in Q3 and the business is currently showing high single-digit growth. Significant digital investments in Bioscience over the course of the year will deliver an enhanced customer experience and improved internal operational efficiency.